(Q44366601)

2 December 2017

title

1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases (English)

1 reference

2 December 2017

Raj N Misra

1

1 reference

2 December 2017

David B Rawlins

2

1 reference

2 December 2017

Hai-yun Xiao

3

1 reference

2 December 2017

Weifang Shan

4

1 reference

2 December 2017

Isia Bursuker

5

1 reference

2 December 2017

Kristin A Kellar

6

1 reference

2 December 2017

Janet G Mulheron

7

1 reference

2 December 2017

John S Sack

8

1 reference

2 December 2017

John S Tokarski

9

1 reference

2 December 2017

S David Kimball

10

1 reference

2 December 2017

Kevin R Webster

11

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Bioorganic & Medicinal Chemistry Letters

2 December 2017

published in

1 reference

2 December 2017

volume

13

1 reference

2 December 2017

issue

6

1 reference

2 December 2017

page(s)

1133-1136

1 reference

Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

1 reference

7 January 2021

The therapeutic potential of targeting the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

[Synthesis of 1H-pyrazolo[3,4-b]pyridine-5-ketones (author's transl)]

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Chemical synthesis and biological activities of 5-deazaaminopterin analogs bearing substituent(s) at the 5- and/or 7-position(s)

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900034-9

7 January 2021

10.1016/S0960-894X(03)00034-9

Identifiers

DOI

1 reference

2 December 2017

1 reference